PsyBio Therapeutics Announces Retention of Market Maker
March 04, 2021 08:08 ET | Source: PsyBio Therapeutics Corp. PsyBio Therapeutics Corp.
TORONTO, March 04, 2021 (GLOBE NEWSWIRE) PsyBio Therapeutics Corp. (TSXV:PSYB) (“
PsyBio” or the “
Company”), a leader in the field of psychedelic research and drug development, announces that, subject to the receipt of approval by the TSX Venture Exchange (“
TSXV”), it has retained Generation IACP Inc. (“
Generation”) to provide market making services with the objective of maintaining a reasonable market and improving the liquidity of PsyBio shares traded on the TSXV. PsyBio and Generation are unrelated and unaffiliated entities. Generation is a member of the Investment Industry Regulation Organization of Canada (IIROC) and a member firm of the TSXV.
PsyBio Completes Reverse Take-Over Transaction Common Shares Expected to Commence Trading on the TSX Venture Exchange Imminently
February 19, 2021 15:17 ET | Source: PsyBio Therapeutics Corp. PsyBio Therapeutics Corp.
Not for distribution to United States newswire services or for release publication,
distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States.
TORONTO, Feb. 19, 2021 (GLOBE NEWSWIRE) PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) (the “
Company”), announces that it has completed its previously announced reverse takeover of PsyBio Therapeutics, Inc. (“
PsyBio”), a biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders (the “